Strauss, Gregory P.
Bartolomeo, Lisa A.
Harvey, Philip D.
Article History
Received: 5 October 2020
Accepted: 9 December 2020
First Online: 26 February 2021
Competing interests
: The authors declare the following competing interests: Gregory P. Strauss was one of the original developers of the Brief Negative Symptom Scale (BNSS) and receives royalties in relation to its commercial use that are donated to brain and behavioral research foundation. Gregory P. Strauss has consulted for or received speaking or travel honorarium from MedAvante-Prophase, Minerva, Lundbeck, and Acadia. Dr. Harvey has received consulting fees or travel reimbursements from Acadia Pharma, Alkermes, Bio Excel, Boehringer Ingelheim, Intra Cellular Therapies, Minerva Pharma, Otsuka Pharma, Regeneron Pharma, Roche Pharma, and Sunovion Pharma during the past year. He receives royalties from the Brief Assessment of Cognition in Schizophrenia. He is chief scientific officer of i-Function, Inc. He has had a research grant from Takeda and from the Stanley Medical Research Foundation.